The FDA prohibited Ranbaxy Laboratories Ltd., from manufacturing and distributing active pharmaceutical ingredients (API) from its facility in Toansa, India, for FDA-regulated drug products, making the Toansa facility subject to certain terms of a consent decree of permanent injunction entered against the pharma in January 2012.